Market Cap$233.82B
P/E30.32x
PEG Ratio2.58
Div yield3.21%
Beta0.44
AMGN Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)13.33%
Price vs S&P 500 (4W)11.33%
PEG Ratio2.58
VGM Score59.85
P/E Ratio (Annual)30.32x
Indicated Dividend Yield (Annual)3.21%
AMGN Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $5.62 | $6.29 | +11.97%(+$0.67) | |
| Q1 2026 | $4.77 | $5.15 | +8.04%(+$0.38) | |
| Q4 2025 | $4.73 | $5.29 | +11.94%(+$0.56) | |
| Q3 2025 | $5.01 | $5.64 | +12.47%(+$0.63) | |
| Q2 2025 | $5.28 | $6.02 | +14.08%(+$0.74) |
AMGN Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.55
3.53
3.53
3.51
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
| TECHBio-Techne Corp. | D | C | B | 9.4x | -0.4% | 66.2% | 6.0% | $72.57 |
About Amgen Inc
Amgen is a leading global biotechnology company with a diversified portfolio spanning oncology, cardiovascular disease, immunology, inflammation, and rare diseases. The company has expanded through strategic acquisitions including Onyx Pharmaceuticals and Horizon Therapeutics, while building a growing biosimilar business alongside marketed drugs across multiple therapeutic franchises. Recent launches demonstrate continued innovation in areas including cardiovascular health, migraine, oncology, and immunology.